Splanchnic vein thrombosis in the patient with cirrhosis: Better anticoagulated than not (for most patients)

In this issue of Thrombosis Research, McMurry and colleagues present the results of a large observational cohort study of adults with cirrhosis and splanchnic vein thrombosis (SVT) who were not initially treated with anticoagulation at the time of SVT diagnosis [1]. Including 269 patients (78?% of whom had isolated portal vein thrombosis) and employing a composite primary endpoint of thrombosis progression and its complications or recurrent thrombosis (SVT progression, development of cavernous transformation, intestinal ischemia, portal cholangiopathy, or new venous or arterial thrombosis), they found that 40?% of these non-anticoagulated patients experienced this primary endpoint.